The Centers for Medicare and Medicaid Services (CMS) recently released justifications for the maximum fair prices it arrived at in negotiations with drug makers for the first 10 medications selected. This move sheds light on the process behind determining the so-called maximum fair prices and provides a glimpse into the negotiation strategies employed by the agency.
The Inflation Reduction Act signed into law by former President Biden in 2022 aimed to lower costs for Medicare beneficiaries by bringing down drug prices and capping out-of-pocket costs. The new Trump administration’s CMS confirmed that the Medicare Drug Price Negotiation Program is on track, but the specifics of the negotiations are yet to be revealed.
CMS announced maximum fair prices for the first ten outpatient drugs selected for negotiation last August. These prices are, on average, 22% lower than the net prices in 2023 and will take effect on January 1, 2026. The negotiation process involved offers and counteroffers between CMS and drug manufacturers.
To determine the initial offer price, CMS identified therapeutic alternatives for each selected drug and gathered pricing information for these competitors. The agency then adjusted the offer price based on the clinical benefit and safety profile of the drug relative to its competitors. Further adjustments were made based on data provided by manufacturers in their counteroffers.
Throughout the negotiation process, CMS considered factors such as therapeutic advances, clinical outcomes, and the impact on specific populations like people with disabilities and the elderly. The agency prioritized direct comparative evidence and evaluated comparative effectiveness data on patient-centered outcomes and experiences.
One notable outcome of the negotiations was the difference in maximum fair prices reached for anticoagulant competitors Eliquis and Xarelto. Despite similar list prices, Eliquis’s maximum fair price was 17% higher than Xarelto’s, possibly due to clinical evidence differences. In another case, the cancer medication Imbruvica saw a significant price cut of approximately 38% due to the ceiling price stipulated by the IRA law.
While the justifications provided insight into the negotiation process, they did not detail how specific clinical and economic data factored into each negotiated maximum fair price. The rationales offered some information on the key value elements considered by CMS during the negotiations but left unanswered questions about the exact calculations and considerations behind the final prices.
Overall, the release of these justifications offers a peek behind the curtain of drug price negotiations under the new legislation, providing a better understanding of the factors and strategies at play in determining maximum fair prices for Medicare beneficiaries. The Trump administration’s CMS recently announced its commitment to incorporating lessons learned from the program and considering opportunities to bring greater transparency to the Negotiation Program. This signals a willingness to adapt and improve the program based on feedback and outcomes.
One key aspect of this commitment is the exploration of new negotiation methods, such as benchmarking overseas prices. This approach could potentially provide a more informed basis for pricing negotiations and help ensure that drug prices are fair and reasonable. By looking at prices in other countries, the program may be able to leverage this information to negotiate better deals with pharmaceutical companies.
The goal of greater transparency in the Negotiation Program is also significant. By making the negotiation process more transparent, stakeholders can better understand how drug prices are determined and how the program is working to lower costs. This can help build trust and accountability in the program, as well as provide valuable insights for future improvements.
It will be interesting to see how these changes are implemented and what impact they will have on drug pricing and access. The flexibility of the program to evolve and adapt under successive administrations is crucial for ensuring its effectiveness and relevance in addressing the challenges of rising drug costs.
Overall, the commitment to incorporating lessons learned and exploring new approaches in the Negotiation Program is a positive step towards improving healthcare affordability and access. By staying open to new ideas and feedback, the program can continue to make progress in addressing one of the most pressing issues in healthcare today.
